Cytora has developed a revolutionary technology to produce “off-the-shelf” (allogeneic) therapeutic doses of hOMSC to treat some of the most challenging diseases of this decade including chronic wounds such as diabetic foot ulcers (DFU) autoimmune and degenerative diseases such as Parkinson’s Disease, Multiple System Atrophy (MSA), and Alzheimer’s Disease.
Milestones
The company successfully completed Phase I/IIa clinical trial in DFU and Phase I MSA patient enrollment into clinical trials.
Building the next generation GMP production line
OUR NEW FACILITY
• Total of 500sqm (offices, labs and clean room).
• 60sqm cGMP manufacturing facility, including in-house cell bank storage in liquid nitrogen and warehouse.
• Cytora’s manufacturing facility is Grade B compliant and includes all the equipment for cell therapy manufacturing process.
• Cytora’s labs are equipped with Real Time PCR, ELISA, fluorescence microscope and other state-of-the-art lab equipment for R&D and QC purposes.
Our Mission
Cytora is on a mission to make it standard practice for people to be treated with off-the-shelf Stem Cell products for some of the most challenging diseases within this decade.
Our Vision
Our vision is to improve and save the lives of millions of patients worldwide through our unique patented stem cell platform technology, making it accessible and affordable.